<div dir="ltr">
<br>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">Dear all,</span><span style="font-size:10pt;font-family:Times"><span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="font-size:10pt;font-family:Times"><span> </span></span></p><p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="font-size:10pt;font-family:Times"><span><br></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">Neural networks are currently considered the most competitive approach for NLP tasks such as Named Entity Recognition (NER), and a number of</span></p><p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">resources and libraries are being implemented to make this track more <br></span></p><p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">efficient (NeuroNER,..etc).<br></span></p><p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black"><br></span></p><p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">We are
currently organizing the first task on chemical and drug mention recognition
from Spanish medical texts, as part of the BioNLP-OST 2019 framework /
EMNLP-IJCNLP 2019.</span><span style="font-size:10pt;font-family:Times"><span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="font-size:10pt;font-family:Times"><span><br></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">Efficient
access to mentions of drugs, medications and chemical entities is a pressing
need shared by biomedical researchers, clinicians and pharma industry. </span><span style="font-size:10pt;font-family:Times"><span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="font-size:10pt;font-family:Times"><span> </span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">I
thought you might also be interested in the track, or potentially have colleagues
that might be interested in either participating or the generated
results/approaches used. <span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">I would
be very grateful if you would help us spread the call. <span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">Best
regards,<span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">Martin<span></span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="font-size:10pt;font-family:Times"><span> </span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="font-size:10pt;font-family:Times"><span> </span></span></p>
<p class="MsoNormal" style="line-height:normal;margin:0cm 0cm 0.0001pt;font-size:11pt;font-family:Arial"><span style="color:black">--------------------------------------------------------------------</span><span style="font-size:10pt;font-family:Times"><span></span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="text-align:center;border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><b><span style="color:black">*** Final Call
for Participation PharmaCoNER – BioNLP-OST 2019 ***<span></span></span></b></p>
<p class="gmail-normal" style="text-align:center;border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><b><span style="color:black"><span> </span></span></b></p>
<p class="gmail-normal" style="text-align:center;border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><b><span style="color:black">Pharmacological
Substances, compounds and proteins and Named Entity Recognition track at
BioNLP-OST 2019 collocated with EMNLP-IJCNLP 2019<span></span></span></b></p>
<p class="gmail-normal" style="text-align:center;border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><b>3 or 4 November 2019 (Hong Kong)<span></span></b></p>
<p class="gmail-normal" style="text-align:center;border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><a href="http://temu.bsc.es/pharmaconer" style="color:blue;text-decoration:underline"><b><span style="color:rgb(17,85,204)">http://temu.bsc.es/pharmaconer</span></b></a><b><span style="color:black"> </span></b><a href="http://temu.bsc.es/meddocan" style="color:blue;text-decoration:underline"><b><span style="color:windowtext"><span></span></span></b></a></p>
<p class="gmail-normal" style="text-align:center;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><b><span> </span></b></p>
<p class="gmail-normal" style="text-align:center;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><span style="font-size:12pt;line-height:115%;color:black">Plan
TL Award <span> </span>for the PharmaCoNER Track <span></span></span></p>
<p class="gmail-normal" style="text-align:center;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial" align="center"><span style="font-size:12pt;line-height:115%;color:black">PharmaCoNER
Awards: 3,400€ total<span></span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:rgb(34,34,34)"><span> </span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><b><span style="color:rgb(34,34,34)">Task description<span></span></span></b></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial">Efficient access to mentions of
drugs, medications and chemical entities is a pressing need shared by biomedical
researchers, clinicians, pharmaceutical industry or even patients. The
recognition of pharmaceutical drugs and chemical entities is a critical step
required for the subsequent detection of drug-related adverse reactions,
drug-repositioning, detection of drug-related fake news, drug-target
associations, just to name a few. <span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial">The critical importance of chemical
and drug name recognition motivated several-shared tasks in the past, such as
the CHEMDNER tracks (<span>Krallinger et al. 2015</span>) or the
i2b2 medication challenge (<span>Uzuner et al. 2010</span>), with a
considerable number of participants and impact in the field. The publications,
corpora and participating systems of these tracks represent influential results
for the community working in biomedical and clinical text mining. <span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial">As part of the BioNLP-OST framework
(<a href="https://2019.bionlp-ost.org/home" style="color:blue;text-decoration:underline"><span style="color:rgb(17,85,204)">https://2019.bionlp-ost.org/home</span></a>),
following the outline of previous chemical and drug NER efforts, we organize<b> <u>the first task on chemical and drug
mention recognition from Spanish medical texts</u></b>. This task will address
the automatic extraction of chemical, drug, gene/protein mentions from clinical
case studies written in Spanish. <span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial">Spanish is a language spoken by more than 572 million
people in the world today, either as a native, second or foreign language. It
is the second language in the world by number of native speakers with more than
477 million people. According to results derived from WHO statistics, just in
Spain there are over 180 thousand practicing physicians, more than 247 thousand
nursing and midwifery personnel or 55 thousand pharmaceutical personnel<span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="margin:0cm 0cm 10pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:rgb(34,34,34)">The PharmaCoNER task will be structured into <b>two sub-tracks</b>:</span><span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black">1) Track 1: NER offset and
entity classification.<span></span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black">2) Track 2: Concept indexing.</span><span></span></p>
<p class="gmail-normal" style="margin:10pt 0cm;line-height:115%;font-size:11pt;font-family:Arial"><b><span style="color:rgb(34,34,34)">Publications</span></b><span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial">As a venue to compile the results of the follow-up
investigation, a journal special issue will be organized to be published a few
months after the workshop. The specific journal will be announced. More
information at the<a href="https://2019.bionlp-ost.org/" style="color:blue;text-decoration:underline"><span style="color:windowtext;text-decoration:none"> </span></a><a href="https://2019.bionlp-ost.org/" style="color:blue;text-decoration:underline"><span style="color:rgb(17,85,204)">BioNLP-OST 2019</span></a>
webpage.<span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><b><span style="color:black">Important Dates<span></span></span></b></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><b><span> </span></b></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>March
18, 2019<span> </span>Sample set and
Evaluation script released. <span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>March
26, 2019<span> </span>Training set released.<span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>March
26, 2019<span> </span>Development set
released. <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>May
31, 2019<span> </span>Test set released
(includes background set). <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>June
25, 2019<span> </span>End of evaluation
period (system submissions). <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>July
1, 2019<span> </span>Results posted and
Test set with GS annotations released. <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>July
19, 2019<span> </span>Working notes paper
submission. <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>TBD<span> </span>Notification of
acceptance (peer-reviews). <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>TBD<span> </span>Camera ready paper
submission. <span> </span><span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span>●<span style="font:7pt "Times New Roman""> </span></span>November,
2019<span> </span>BioNLP-OST 2019 Workshop (to
be collocated with EMNLP-IJCNLP 2019, Hong Kong)<span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black">Additional information is
available at:<span></span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span style="font-family:Symbol;color:black"><span>·<span style="font:7pt "Times New Roman"">
</span></span></span><a href="http://temu.bsc.es/pharmaconer" style="color:blue;text-decoration:underline"><span style="color:rgb(17,85,204)">http://temu.bsc.es/pharmaconer</span></a><span style="color:black"> <span></span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span style="font-family:Symbol;color:black"><span>·<span style="font:7pt "Times New Roman"">
</span></span></span><span style="color:black"><a href="https://2019.bionlp-ost.org" style="color:blue;text-decoration:underline">https://2019.bionlp-ost.org</a><span></span></span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt 36pt;border:medium none;line-height:115%;font-size:11pt;font-family:Arial"><span style="font-family:Symbol;color:black"><span>·<span style="font:7pt "Times New Roman"">
</span></span></span><span style="color:black"><span> </span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial">Best regards,<span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span></p>
<p class="gmail-normal" style="margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span> </span><span> </span>Martin Krallinger<span></span></p>
<p class="gmail-normal" style="border:medium none;margin:0cm 0cm 0.0001pt;line-height:115%;font-size:11pt;font-family:Arial"><span style="color:black"><span> </span></span></p>
<br clear="all"><br>-- <br><div dir="ltr" class="gmail_signature" data-smartmail="gmail_signature"><div dir="ltr"><div><div dir="ltr"><div><div dir="ltr"><div><div dir="ltr"><div><div dir="ltr"><div><div dir="ltr"><div><div dir="ltr"><div>=======================================<br>Martin Krallinger, Dr.<br>--------------------------------------------------------------------<br><span style="font-family:arial,helvetica,sans-serif">Head of Biological Text Mining Unit<br>Barcelona Supercomputing Center (BSC-CNS)</span><br>--------------------------------------------------------------------<br>Oficina Técnica General (OTG) del Plan TL en el <br>área de Biomedicina de la <span><i>Secretaría de Estado <br></i></span></div><div><span><i>para</i> el Avance Digital</span><div style="margin-left:80px"> <span><img src="https://docs.google.com/uc?export=download&id=0BxG-jzUayUmhZ2djTzRVUU8zNnM&revid=0BxG-jzUayUmhWTNWa0k3c2NZQU9qVzdBRzY2UUhibldVUzVvPQ" width="96" height="36"></span><br></div>
<span>=======================================</span><br></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>